ArticleOncology research2026
piR-37524 Overexpression in Colorectal Cancer: A Potential Diagnostic Bio-Marker and Therapeutic Target.
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Piwi-associated RNAs are small non-coding RNAs implicated in cancer, yet few have been characterized in colorectal cancer (CRC). This study aimed to identify a CRC-related piRNA and investigate its clinical relevance, biological function, and biomarker potential. Methods: Candidates were identified by reanalysis of small-RNA sequencing. piR-37524 was quantified by quantitative real-time polymerase chain reaction (qRT-PCR) in colorectal cancer tissues, matched adjacent non-tumor tissues, colorectal adenomas, liver metastases, and serum samples from patients and healthy controls. Clinicopathological correlations and diagnostic performance were evaluated. Functional assays included 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation, colony formation, and wound-healing migration in HCT116 and HT29 cells after piR-37524 inhibition. RNA sequencing and Western blotting examined epithelial-mesenchymal transition (EMT) markers and nuclear factor-kappa B (NF-κB) components. Results: piR-37524 was significantly overexpressed in CRC compared with adjacent non-tumor tissues and was associated with larger tumor size, poorer differentiation, and distant metastasis. Elevated expression was also observed in colorectal adenomas and liver metastases. Serum piR-37524 levels were increased in patients with adenomas and CRC compared with healthy controls, indicating diagnostic potential. Functional assays demonstrated that piR-37524 inhibition suppressed CRC cell proliferation and migration, accompanied by changes consistent with epithelial-mesenchymal transition regulation. Mechanistic analyses implicated tumor necrosis factor alpha-induced protein 3 (TNFAIP3)-associated NF-κB signaling. Conclusions: piR-37524 is an oncogenic piRNA in CRC that promotes progression via the TNFAIP3/NF-κB/EMT axis, serving as a potential pan-stage diagnostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.